Ozempic (semaglutide) was initially approved for the treatment of people with Type 2 diabetes, and is part of a popular new class of medications known as glucagon-like peptide-1 receptor agonists (GLP-1RAs)
How can I cancel the subscription
By targeting GIP receptors in the brain as well as GLP-1, it may increase a sense a satiety and reduce intake even more than those that target GLP-1 receptors alone, Greenberg says
lateral ventricle and medial preoptic area injections demonstrated local effects The subcutaneous route ultimately proved most suitable for clinical development, offering reliable absorption, manageable side effects, and practical at-home self-administration
The STEP 1 trial, published in the New England Journal of Medicine in 2021, showed that participants taking semaglutide 2.4 mg weekly lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% in the placebo group